PRINCETON, N.J., Oct. 1 NJ-Pharmasset-JMPconf
PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS) management will present at the Third Annual JMP Securities
Healthcare Focus Conference being held from October 6-7, 2008 at the Le Parker
Meridien in New York City. Schaefer Price, Pharmasset's Chief Executive
Officer, will provide an overview of the company on Monday, October 6, 2008,
from 10:00-10:30 AM (ET).
To access a live webcast of Mr. Price's overview via the internet, log on
to the "Events & Presentations" section of the Investor Center on Pharmasset's
website at http://investor.pharmasset.com/events.cfm . Please connect to the
website at least ten minutes prior to the start of the presentation to ensure
adequate time for a reliable connection and any software download that may be
necessary for the webcast.
A replay of the webcast will be available on Pharmasset's website for
thirty days following the conference. The investor presentation will be
available for download in PDF format immediately following the presentation in
the "Events & Presentations" section of the Investor Center on Pharmasset's
website at http://investor.pharmasset.com/events.cfm .
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by Bukwang
Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral
treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in
combination with Pegasys(R) plus Copegus(R) through a strategic collaboration
with Roche. Racivir, which is being developed for the treatment of HIV in
combination with other approved HIV drugs, has completed a Phase 2 clinical
trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Kurt Leutzinger
Chief Financial Officer
kurt.leutzinger@pharmasset.com
Office: +1 (609) 613-4110
SOURCE Pharmasset, Inc.
